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Objectives
• Review the HIV epidemic
• Describe preconception counseling, testing, assessment & therapy of
both the mother’s & newborn’s HIV
• Discuss aspects of medical care prior to, throughout, & posthospitalization of the mother’s & newborn’s HIV
• Summarize the continuation of care post hospitalization with an
emphasis on adherence to medical care, issues associated with
breast feeding & pre-mastication

No Disclosures

Georgia Epidemiology: 2016
• 5th highest: total number of new diagnoses of HIV
• December 31, 2016: 56,789 persons living with HIV infection
– 2,593 persons were diagnosed in 2016
– 64% living with HIV infection reside in the Atlanta area

• Black or African American alone, July 1, 2016 - 32%
New Diagnoses of HIV by Race/Ethnicity, GA, 2015

http://dph.georgia.gov/data-fact-sheet-summaries
http://www.census.gov/quickfacts/table/PST045215/13

New Diagnoses of HIV, by Sex & Transmission among
Adolescents & Adults (13 years and older), Georgia, 2015

Number & Rates: Persons Living with HIV & AIDS, GA, through December 31, 2016

https://dph.georgia.gov/sites/dph.georgia.gov/files/HIV_EPI_Fact%20Sheet_Georgia%202015_04.14.17.pdf

HIV Incidence: Estimated Annual Infections in the U.S.
2008-2014 Overall and by Transmission Route

20% increase among Latino gay and bisexual men (from 6,100 to 7,300)
Increased among men ages 25-34
Southern states: greatest burden- 50% of new infections; 2014
Annual HIV infections declined:
Washington, D.C. 10% per year
Maryland about 8% per year
Georgia about 6% per year
New York and North Carolina each about 5% per year
https://www.cdc.gov/nchhstp/newsroom/docs/factsh
eets/hiv-incidence-fact-sheet_508.pdf

Ryan White Part B Clinics:
Clients Retained in Care
HIV Viral Load Suppression: 80%

Georgia DPH Resource HUB

https://www.gacapus.com

Georgia Law
Generally requires notification to the patient before an HIV test is performed. According to the
statute, a health care provider who orders an HIV test “shall do so only after notifying the person to
be tested;” the notification must be “prior to drawing the body fluids;” and the person “shall have
the opportunity to refuse the test.” O.C.G.A. § 31-22-9.2(c).
This can be accomplished by adding some simple notification and opt-out language to an existing
medical consent form. Although the law contains no requirement that the consent/opt-out to be in
writing, it is definitely the better practice.

Prior notice and consent of the patient is not required if:
• Testing is mandatory under one of the following statutes:
o O.C.G.A. § 15-11-603 (court-ordered testing of juvenile who committed AIDS-transmitting crime);
o O.C.G.A. § 17-10-15 (court-ordered testing of adult convicted of AIDS-transmitting crime);
o O.C.G.A. § 31-17-4.2 (providers must test pregnant women unless they specifically refuse);
o O.C.G.A. § 31-17A-3 (DPH can petition superior court to test person suspected of HIV infection
with clear and convincing evidence of “compelling need to protect public health”);
o O.C.G.A. § 42-5-52.1 (HIV testing required for all inmates); or
o O.C.G.A. § 42-9-42.1 (HIV test results may be considered in deciding clemency, pardon, or parole);
• The person is a minor or incompetent and the parent or guardian consents;
• The person is unconscious, comatose, or temporarily incompetent and the next of kin consents;
• “The physician ordering the test is of the opinion that the person to be tested is in such a medical or
emotional state that disclosure of the test would be injurious to the person’s health;” or
• There is an emergency or life-threatening situation.

Georgia Law
No counseling is required (and it may even be counterproductive) before the test is
performed. The provider is required to give “medically appropriate counseling” regarding the
test results “when the last confirmatory test has been completed.” O.C.G.A. § 31-22-9.2(d)
Medically appropriate counseling may consist of:
•
•
•
•
•

Accurate information regarding AIDS and HIV;
An explanation of behaviors that may reduce the risk of transmission;
An explanation of the confidentiality of HIV/AIDS information;
Information regarding “both social and medical implications of HIV tests;” and/or
Information regarding “commonly recognized treatment.”

O.C.G.A. § 31-22-9.1(a)(6).
Under the statute, the counseling “may include all or a part of” the above topics.
O.C.G.A.§31-17-7(a): any minor may consent to the treatment of a sexually transmitted
disease or any illness or condition arising from having contracted a sexually transmitted
disease without parental consent

Health Information Exchange
Senate Bill 342

"The Department of Public Health may disclose
AIDS confidential information regarding a person
who has been reported, under paragraph (1) or (2) of
subsection (h), to be infected with HIV to a health
care provider licensed pursuant to Chapter 11, 26, or 34
of Title 43 whom that person has consulted for
medical treatment or advice."
Signed by the Georgia Governor: April 29, 2014

Initiation of ARVs
Increased harmful impact of ongoing HIV replication
Preventing secondary transmission (96% reduction)

BUT
Client should be willing and able to commit to therapy

Postponement of therapy may needed
Based on clinical and/or psychosocial factors

Acknowledgment: Elizabeth Race, MD MPH

Genotype:
Phenotype:

genetic code of the sample virus is compared to the wild type
sample of HIV is grown with each ARV

http://hivdb.stanford.edu/
http://www.iasusa.org/resistance_mutations

NsRTIs
AZT
ddI
ddC
d4T
3TC
ABC
FTC

Zidovudine /Retrovir
Didanosine /Videx*
Zalcitabine /Hivid*
Stavudine /Zerit*
Lamivudine /Epivir
Abacavir /Ziagen
Emtricitabine /Emtriva

NtRTIs
TDF/TAF Tenofovir /Viread

NNRTIs
NVP
DLV
EFV
ETV
RPV

Nevirapine /Viramune
Delavirdine /Rescriptor
Efavirenz /Sustiva
Etravirine /Intelence
Rilpivirine /Edurant

Booster
COBI

Cobicistat /Tybost

Protease Inhibitors
SQV
RTV
IDV
NFV
APV
LPV/r
ATV
FPV
TPV
DRV

Saquinavir /Invirase
Ritonavir /Norvir
Indinavir /Crixivan
Nelfinavir /Viracept
Amprenavir /Agenerase
Lopinavir /Ritonavir (Kaletra)
Atazanavir /Reyataz
Fosamprenavir /Lexiva
Tipranavir /Aptivus
Darunavir /Prezista

Entry Inhibitor
T-20*
MVC
Ibalizumab

Enfuvirtide /Fuzeon
Maraviroc /Selzentry
CD4 postattachment inh

Integrase Inhibitor
RAL
DTG
EVG
BIC

Raltegravir /Isentress (HD)
Dolutegravir /Tivicay
Elvitegravir /Vitekta
Biktegravir

•

Lamivudine, Zidovudine
– Combivir™ (gen)

•

Abacavir, Lamivudine
– Epzicom™

•

$1,738.46

Efavirenz, Emtriva, TDF
– Atripla™

•

$1,759.73

Abacavir, Zidovudine, Lamivudine
– Trizivir™ (gen)

•

$1,539.90

Emtriva, Tenofovir Alafenamide (TAF)
– Descovy™

•

$1,416.35

Emtricitabine, Tenofovir (TDF)
– Truvada™

•

$931.61

$2,551.99

Rilpivirine, Emtriva, TDF
– Complera™ $2,463.37

•

Emtriva, Rilpivirine, TAF
• Odefsey™

•

$2,815.04

Elvitegravir, cobi, Emtriva, TDF
– Stribild™

$2,948.70

• Elvitegravir, cobi, Emtriva, TAF
• Genvoya™

$4,182.52

• Dolutegravir, Abacavir, Lamivudine
• Triumeq™

• Darunavir, Cobicistat
• Prezcobix™

• Atazanavir, Cobicistat
• EvoTaz™

• Dolutegravir, Rilpivirine
• Juluca™

$2,648.84

$1,725.29
$1,684.44
$2,583.33

• Bictegravir, Emtriva, TAF
•

Biktarvy™

$2,945.65

• Darunavir, cobi, Emtriva, TAF
• Symtuza™

$3,482.00

July 18, 2018: Symtuza™ FDA Approved

Preconception Counseling
• Reproductive Options
• Safe Sexual Practices / Treat STIs
• Initiate ARVs –› consider co-morbidities: hep B
• Consider partner HIV treatment or PrEP
– Pre-exposure prophylaxis

• Fewer than 200 HIV-infected infants
– born each year in the United States

• Sentinel Event
http://contemporaryobgyn.modernmedicine.com/contemporary-obgyn/content/tags/centers-disease-control-andprevention/preconception-health-indicato?page=full

Initial Assessment
Review past HIV-related illnesses & previous therapy
 Education: benefits of therapy
 Check a Genotype (do not delay therapy)








Check CBC, CMP, HLA B5701 (if Ziagen considered)
Check current CD4 and Viral Load
Assess need for OI prophylaxis or treatment
Hepatitis A / B / C / Tb assessment
Assess immunization needs

◦ Hepatitis A/B, influenza, pneumococcus, Tdap
 Assess supportive care & adherence
 Close follow up with a team approach
The National Perinatal HIV Hotline:
1-888-448-8765
Antiretroviral Pregnancy Registry:
1-800-258-4263
http://www.apregistry.com
http://aidsinfo.nih.gov/contentfiles/perinatalGL.pdf

Rapid Testing

Georgia HIV/Syphilis Pregnancy
Screening Act of 2015; enact
House Bill 436 / § 31-17-4.2: Signed May 12, 2015

Every physician/HCP who assumes responsibility of care
…shall be required to test for HIV & syphilis except in
cases where the woman refuses. Additionally, … during
the 3rd trimester shall offer HIV & syphilis tests at the
time of 1st exam regardless of whether testing was
performed during the first 2 trimesters.

https://www.cdc.gov/std/stats16/msm.htm
https://www.cdc.gov/std/stats16/default.htm
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Georgia Concerns
Georgia National Rank (2016)

STD

Cases

Rate per 100,000 population

3

Gonorrhea

20,553

201.2

4

P&S Syphilis

1,350

13.2

5

Chlamydia

62,776

614.6

9

Congenital Syphilis

21

16

10

P&S Syphilis (women)

113

2.2

https://www.cdc.gov/std/stats16/toc.htm

https://dph.georgia.gov/sites/dph.georgia.gov/files/HIV_EPI_2010-2016_Trends%20Fact%20Sheet.pdf

Prevention of Perinatal Transmission
• All pregnant women with acute/chronic HIV
– should receive/continue ARVs to prevent MTCT

• Key
–
–
–
–

Taking ART for 24 weeks or more
ART initiation prior to 28 weeks’ gestation
Viral Load of < 50 copies/mL near delivery
Prophylaxis of the newborn

• Reduced transmission rate:
– 20% to 30% reduced to < 0.5%
– 0.09% if HIV-VL < 50 copies/mL (UK data)

Risk Factors
•
•
•
•
•
•
•
•

Maternal viral load
Duration of ruptured membranes (2% incr. for ea. hour)
Internal fetal monitoring / Amniocentesis*
Forceps, vacuum extractors, episiotomy
Mode of delivery*
Low birth rate
Genital tract infections
Cigarette smoking / Substance abuse
Primary HIV-infection in pregnancy

Timing

Risk with no intervention

Pregnancy

5-10%

Labor and Delivery

10-20%

Breastfeeding

5-20%

MTCT, 2000-2006, 5,930 births to HIV+ Women, UK/Ireland
Townsend CL, et al. AIDS 2008;22:973-981
Prophylaxis

MTCT

Adjusted OR

Overall

1.2%

ART > 14 days

0.8%

HAART with NNRTI

0.9%

HAART with PI

1.1%

HAART at conception

0.1%

HAART during pregnancy

1.3%

HAART elective CS

0.7%

HAART planned vaginal

0.7%

AZT elective CS (N=464)

0%

1.31 (0.6-2.8) p=0.48

0.18 (0.02-1.3) p=0.09

P=0.15

Cesarean section for HIV-infected women in the
combination antiretroviral therapies era, 2000-2010
• Vaginal deliveries incr. 25% in 2000 to 53% in 2010
• MTCT rate did not differ according to mode of delivery
– In term deliveries (≥37 gestational weeks)
– 0.3% after both vaginal delivery and elective CS with VL <50
– 4.0% vs 5.3%, respectively, with VL ≥10,000 copies/mL
• Preterm delivery
– MTCT rates tended to be higher with vaginal delivery
– Postpartum complications were more frequent following CS than
vaginal deliveries (6.5% vs 2.9, P < .01)
• CONCLUSION:
– Suggest that HIV-infected women on ARVs with low VL can safely opt
for vaginal delivery in the absence of obstetrical risk factors
Am J Obstet Gynecol. 2013 Oct;209(4):335.e1-335.e12. doi: 10.1016/j.ajog.2013.06.021. Epub 2013 Jun 18

C-Section
Recommend C-Section at 38 Weeks
IF HIV RNA > 1000 copies/mL or Unknown
Acute HIV infection during pregnancy
Especially if occurring late in pregnancy
IF HIV RNA < 1000 copies/mL and C-sect scheduled
perform at 39 weeks for standard OB indications
Still give prophylactic antibiotics within 60 min of skin incision
Cefazolin: 2grms for pts <120kg & 3grms for pts ≥120 kg
Clinda / Gent: 900 mg / 5 mg/kg IV

Preferred Therapy / Follow Up
Check Resistance Testing
May start therapy with a PI based regimen if:
HIV conversion occurs during pregnancy
• Fetal ultrasound at 18 to 20 weeks
– If on Efavirenz at the time of pregnancy

• HIV-VL: 2-4 weeks after starting/changing HAART
– Then monthly until undetectable & at 34-36 weeks

• Glucose screening at weeks 24-28 esp. if on a PI

DHHS 2017 Guidelines

June 4: Prezcobix

March 18, 2018
FDA Drug Safety Alert
Botswana identified neural tube defects in 4 infants born to 426 women who initiated a DTGbased regimen prior to pregnancy, & who were still receiving it at the time of conception

https://www.cdc.gov/ncbddd/birthdefects/data.html
http://www.who.int/bulletin/volumes/94/1/14-151365/en/

Preliminary Data Suggest Increased Risk of Neural Tube Defects (NTDs)
With Dolutegravir (DTG) Exposure at Conception
Tsepamo: birth outcomes surveillance study / Summary of Key Conclusions
• Unplanned analysis of ongoing birth outcomes surveillance study among Botswanan
women with and without HIV infection detected preliminary increase in prevalence of
NTDs among infants exposed to DTG at conception
•NTD prevalence: DTG exposure at conception: 4/426 (0.94%; 95% CI: 0.37% - 2.4%)
•1 case each- encephalocele, anencephaly, myelomeningocele, iniencephaly
• NTD prevalence: other subgroups
• non-DTG ART at conception (0.12%), efavirenz at conception (0.05%),
• DTG started during pregnancy (0.00%), and HIV-negative women (0.09%)
• At latest analysis, July 2018:
• NTD prevalence: DTG exposure at conception: 4/596 (0.67%; 95% CI: 0.26% - 1.7%)
• NTD prevalence: DTG started in pregnancy: 1/3104 (0.03%; 95% CI: 0.01% - 0.18%)
Investigators suggest that this preliminary, early signal needs further data and analysis
Source:

22nd International AIDS Conference
Released: July 27, 2018

AZT at the Time of Delivery
• IV AZT: Administer
• If HIV RNA >1000 copies/mL
• Unknown HIV RNA near delivery
• Regardless of antepartum regimen or mode of delivery

• IV AZT: Not required
• On combination ARV regimens & no concerns of adherence
• And a sustained HIV RNA ≤1000 copies/mL

• IV AZT during labor: (even if AZT resistant)
•
•
•
•

Stop oral AZT, if IV AZT started; continue all other oral agents
If C-sect scheduled – start 3 hours prior to procedure
2 mg/kg body weight IV over 1 hour, then
1 mg/kg body weight IV per hour until delivery

Additional Considerations
Postpartum bleeding resulting from uterine atony
– Protease Inhibitors / Cobi
• Methergine use if NO alternative agents available
– i.e. prostaglandin F2-alpha, misoprostol, oxytocin
• Treatment outweighs the risk
• Lowest effective dose used for the shortest possible duration

– NNRTIs
• Methergine levels decreased with inadequate treatment effect
• Additional urotonic agents may be needed

All HIV-Exposed Infants
§ Neonate: 6 Weeks of AZT Therapy
§ No benefit if started after 48 hours + infection established after 14 days
§ >= 35 wks gestation: 4 mg/kg po Q12H within 6-12 hours
§ 3 mg/kg/dose IV, if unable to tolerate PO
§ < 35 wks: 2 mg/kg po Q12H then increase dose as noted below:
§ 1.5 mg/kg/dose IV Q12H, if unable to tolerate PO
§ if >= 30wks gestation

» advance to 3 mg/kg/dose PO Q12H at age 15 days
» 2.3 mg/kg/dose IV Q12H, if unable to tolerate PO
§ if < 30wks gestation

» advance to 3 mg/kg/dose PO Q12H after age 4 weeks
» 2.3 mg/kg/dose IV Q12H, if unable to tolerate PO

2016 Update
• 4 week chemoprophylaxis may be considered
– Full term infants
– Mother received standard antiretroviral therapy
– No concerns with adherence during pregnancy
– Consistent viral suppression
• VL < 1,000 copies near the time of delivery

– No prolonged rupture of membranes or obstetric
complications including cord prolapse

High Risk Deliveries
§ Consider 3 doses of Nevirapine for high risk deliveries
§ Late presenters, lack of maternal VL suppression, resistant HIV

§ Dose at birth – 48hrs, 48 hrs later, 96 hrs after the 2nd dose

§ Birth weight 1.5–2 kg: 8 mg total per dose given orally
§ Birth weight >2 kg: 12 mg total per dose given orally

https://www.flickr.com/photos/blyth/1074446532

Trimethoprim / Sulfamethoxazole
• To prevent Pneumocystis jirovecii pneumonia
• Given to ALL infants born to HIV-infected women
• Initiate at ages 4 to 6 weeks
– Start after completing their ARV prophylaxis regimen
– Unless adequate test data to presumptively exclude HIV

• TMP-SMX: 150/750 mg/m2 body surface area per day
– Max daily dose: 320/1600 mg orally
– Alternative dosing if given:
QMWF
OR
– Administered 3 times weekly on consecutive day

HIV Infected Newborns
DO NOT

delay triple therapy while awaiting studies
AZT/3TC/Nevirapine

Stop prophylaxis if mother’s HIV testing returns negative
If mother’s test is positive: perform HIV DNA PCR assay on newborn
Newborn HIV DNA or RNA PCR testing
Within first 14-21 days of life, at 1-2 mnths, at 4-6 mnths
TWO positive tests constitute a diagnosis of HIV
If HIV diagnosed in newborn: stop 1 or 2 drug prophylaxis
Assessment/Treatment by a pediatric HIV specialist
No evidence: using maternal resistance test results improves outcomes

Interruption of Therapy After Pregnancy
Maternal therapeutic indications are the same
as for other nonpregnant individuals

BUT: use caution if stopping HAART
Extend NRTIs 7 to 30 days if stopping a NNRTI (or)
Add a Boosted PI to the NRTIs for the 7 to 30 day period
Caution with HIV / Hepatitis B co-infected clients

Breastfeeding & Pre-mastication of Food
• Avoid breastfeeding: confirmed HIV pos. women
• Pumping and discarding or freezing milk
– If confirmatory testing is pending

• Replacement feeding
– Affordable, feasible, acceptable, sustainable, safe
– Low risk of mortality: diarrheal & respiratory disease

• Routinely inquire about pre-mastication of food

Perinatal Transmissions by
Mother’s Residence, 2009-2017
10
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* May be incomplete

§ 31-17-4.2: Georgia HIV/Syphilis Pregnancy Screening Act of 2015; enact

Gregory S. Felzien, M.D., AAHIVS
Diplomat: Internal Medicine and Infectious Disease

Georgia Department of Public Health
Medical Advisor
Division of Health Protection/IDI-HIV
gregory.felzien@dph.ga.gov

